Literature DB >> 12832243

Insurance expenditures on bipolar disorder: clinical and parity implications.

Pamela B Peele1, Ying Xu, David J Kupfer.   

Abstract

OBJECTIVE: This study assessed treatment rates and expenditures for behavioral health care by employers and behavioral health care patients in a large national database of employer-sponsored health insurance claims.
METHOD: Insurance claims from 1996 from approximately 1.66 million individuals were examined. Average annual charges per person and payments for behavioral health care were calculated along with patient out-of-pocket expenses and inpatient hospital admission rates. Behavioral health care expenditures for bipolar disorder were compared to expenditures for other behavioral health care diagnoses in these same insurance plans.
RESULTS: A total of 7.5% of all covered individuals filed a behavioral health care claim. Of those, 3.0% were identified as having bipolar disorder, but they accounted for 12.4% of total plan expenditures. Patients with bipolar disorder incurred annual out-of-pocket expenses of $568, more than double the $232 out-of-pocket expenses incurred by all claimants. The inpatient hospital admission rate for patients with bipolar disorder was also higher (39.1%) compared to 4.5% for all other behavioral health care claimants. Furthermore, annual insurance payments were higher for covered medical services for individuals with bipolar disorder than for patients with other behavioral health care diagnoses.
CONCLUSIONS: Bipolar disorder is the most expensive behavioral health care diagnosis, both for patients with bipolar disorder and for their insurance plans. For every behavioral health care dollar spent on outpatient care for patients with bipolar disorder, $1.80 is spent on inpatient care, suggesting that better prevention management could decrease the financial burden of bipolar disorder.

Entities:  

Mesh:

Year:  2003        PMID: 12832243     DOI: 10.1176/appi.ajp.160.7.1286

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  46 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Mental health service use by children with serious emotional and behavioral disturbance: results from the LAMS study.

Authors:  Amy N Mendenhall; Christine Demeter; Robert L Findling; Thomas W Frazier; Mary A Fristad; Eric A Youngstrom; L Eugene Arnold; Boris Birmaher; Mary Kay Gill; David Axelson; Robert A Kowatch; Sarah McCue Horwitz
Journal:  Psychiatr Serv       Date:  2011-06       Impact factor: 3.084

3.  Mood disorder symptoms and elevated cardiovascular disease risk in patients with bipolar disorder.

Authors:  Juliette M Slomka; John D Piette; Edward P Post; Sarah L Krein; Zongshan Lai; David E Goodrich; Amy M Kilbourne
Journal:  J Affect Disord       Date:  2012-02-21       Impact factor: 4.839

4.  Incurring greater health care costs: risk stratification of employees with bipolar disorder.

Authors:  Richard A Brook; Krithika Rajagopalan; Nathan L Kleinman; James E Smeeding; Truman J Brizee; Harold H Gardner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 5.  The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.

Authors:  Sean H Yutzy; Chad R Woofter; Christopher C Abbott; Imad M Melhem; Brooke S Parish
Journal:  J Nerv Ment Dis       Date:  2012-05       Impact factor: 2.254

6.  Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.

Authors:  Yawen Jiang; Weiyi Ni; Justin J McGinnis
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

7.  Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders.

Authors:  Andrew C Leon; Jess G Fiedorowicz; David A Solomon; Chunshan Li; William H Coryell; Jean Endicott; Jan Fawcett; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

8.  Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry.

Authors:  Carol A Janney; Andrea Fagiolini; Holly A Swartz; John M Jakicic; Robert G Holleman; Caroline R Richardson
Journal:  J Affect Disord       Date:  2013-09-18       Impact factor: 4.839

9.  Bipolar-I depression outpatient treatment quality and costs in usual care practice.

Authors:  Alisa B Busch; Richard G Frank; Gary Sachs
Journal:  Psychopharmacol Bull       Date:  2008

10.  Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies.

Authors:  R Bruce Lydiard; Larry Culpepper; Helena Schiöler; Urban Gustafsson; Björn Paulsson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.